Salute e Benessere

Systemair AB Interim Report Q3 2024

Roland Kasper, President and CEO, comments: Roland Kasper, President and CEO, comments: "Systemair's third quarter, which covers November to January, is normally our weakest quarter, except for the previous year which was unusually strong. We see achieving an organic growth of 0.1 percent as a statement of strength. The adjusted operating profit for the period amounted toSEK 198 M(277). We are very satisfied that during the period we signed a series of strategic and large...
PR Newswire
05/03/2024

Mithra announces changes to its executive management

Mithra announces changes to its executive managementLiege, Belgium, 05 March 2024 – 07:00 CET– Mithra (Euronext Brussels: MITRA), a company dedicated to women's health, today announces the termination of the management agreement with David Horn Solomon 1as CEO and his replacement by Christophe Maréchal 2and Xavier Paoli as co-CEOs.As announced today, Mithra will commence a monetization process involving the sale of various selected assets of Mithra and/or the business as a whole...
Nasdaq GlobeNewswire
05/03/2024

Mithra initiates monetization process, receives bridge loan from existing…

Mithra initiates monetization process, receives bridge loan from existing lendersMithra appoints advisors and initiates a process to monetize its assets or execute a sale of its businessMithra has entered into a new secured bridge loan facility in a committed amount of up to EUR 13.5 million, subject to milestones; with an uncommitted facility of a further EUR 5 millionBridge loan facility provides expected liquidity runway to fund the monetization process with respect to key...
Nasdaq GlobeNewswire
05/03/2024

Sandoz announces nominations to the Board of Directors and leadership change

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEMathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General MeetingRemco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of DirectorsColin Bond to retire as CFO of Sandoz on June 30, 2024Basel, March 5, 2024- The Board of Directors...
Nasdaq GlobeNewswire
05/03/2024

CARBIOS Active, the enzymatic solution for 100% compostable PLA, added to FDA…

CARBIOS Active, the enzymatic solution for 100% compostable PLA, added to FDA Inventory of Food Contact SubstancesPLA 1packaging integratingCARBIOS Activeis 100% compostable even at ambient temperatures, supporting Food & Beverage brands in achieving their sustainability commitmentsClermont-Ferrand, France, Tuesday 5 March 2024 (06.45am CET) CARBIOS(Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent...
Nasdaq GlobeNewswire
05/03/2024

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

The acquisition of ARTMS is expected to further enhance the vertical integration of Telix's supply chain and manufacturing by providing a greater level of control and security over each of the Company's diagnostic isotopes. The acquisition of ARTMS is expected to further enhance the vertical integration of Telix's supply chain and manufacturing by providing a greater level of control and security over each of the Company's diagnostic isotopes. ARTMS' core technology platform is based on the...
PR Newswire
05/03/2024

DBV Technologies to Report Full Year 2023 Financial Results and Business Update…

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatments for food allergies, today announced the Company will host a conference call and live audio webcast on Thursday, March 7th, at 5:00 p.m. ET to review full year 2023 financial results and provide a business update.Interested participants may access...
Nasdaq GlobeNewswire
04/03/2024

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)Listing market: Euronext GrowthISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights 02/29/202471,751,20177,686,895 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33...
Nasdaq GlobeNewswire
04/03/2024

Biogen Highlights New Data at the International Conference on Alzheimer's and…

New data advances understanding of new approaches to treating Alzheimer's disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March04, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) announced it will present new data from its Alzheimer's disease (AD) portfolio at the upcoming International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2024), taking place March 5-9 in Lisbon, Portugal and virtually. The presentations...
Nasdaq GlobeNewswire
04/03/2024

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; March 4, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...
Nasdaq GlobeNewswire
04/03/2024

Information on the Total Number of Voting Rights (Denominator) following…

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion...
Nasdaq GlobeNewswire
04/03/2024

Early Diagnosis & Remote Monitoring Fuel 8.2% CAGR in Wearable Medical Device…

Fueling this growth is the increasing burden of diseases on healthcare systems due to irregular hospital visits and sedentary lifestyles. This compels healthcare bodies, medical service providers, and governments to prioritize timely and regular diagnoses for patients. This, in turn, has created a conducive environment for manufacturers of wearable medical devices. Fueling this growth is the increasing burden of diseases on healthcare systems due to irregular hospital visits and sedentary…
PR Newswire
04/03/2024

Resolutions from the Extraordinary Shareholders' Meeting 2024

Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders' meeting was conducted. The following resolutions were made :Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewithElection of Jesper Brandgaard as Vice Chair of the Board of DirectorsElection of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors Following the extraordinary shareholders' meeting, the Board of...
Nasdaq GlobeNewswire
04/03/2024

Point of Care Diagnostics Market Worth $77.8 billion | MarketsandMarkets™

Browse in-depth TOC on "Point of Care Diagnostics Market" Browse in-depth TOC on "Point of Care Diagnostics Market" 191 - Tables51 - Figures322 - Pages Point of Care Diagnostics Market Scope: Pricing pressure due to reimbursement cuts and limited budgets along with strict regulatory approval process for new point of care product commercialization are factors expected to restrain market growth during the forecast period. The Lateral Flow Assays segment, by platform,...
PR Newswire
04/03/2024

Regulatory approvals granted for the public offer in Essity's subsidiary Vinda

CONTACT: CONTACT: For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55,per.lorentz@essity.comSandra Åberg, Vice President Investor Relations, +46 70 564 96 89,sandra.aberg@essity.com The following files are available for download: View original content: https://www.prnewswire.co.uk/news-releases/regulatory-approvals-granted-for-the-public-offer-in-essitys-subsidiary-vinda-302078630.html
PR Newswire
04/03/2024

Novo Nordisk A/S - share repurchase programme

Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 04 March 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a…
Nasdaq GlobeNewswire
04/03/2024

Optimum Nutrition Launches New Global Marketing Campaign "Unlock More You"

Launching in over 100 markets around the world, the new campaign is the latest work inspired by the brand's core creative idea that 'there's more of you in you.' It continues the brand's journey of democratising the sports nutrition category by taking it beyond the gym and showing that no matter what your sport or motivation is, with the right mindset, you can unlock more from yourself with help from Optimum Nutrition. Launching in over 100 markets around the world, the new campaign is the...
PR Newswire
04/03/2024

Cyient Partners with MassMedic to Accelerate MedTech Innovation

"Joining MassMedic marks a significant milestone in our journey toward becoming a key enabler in the MedTech industry," said Anand Parameswaran, President and Business Head – Healthcare & Life Sciences, Cyient. "Our goal is to leverage our deep domain knowledge and digital expertise to accelerate innovation, improve patient outcomes, and reduce healthcare costs." "Joining MassMedic marks a significant milestone in our journey toward becoming a key enabler in the…
PR Newswire
04/03/2024

Berlin Cures' BC 007 Targets Long COVID: Solid Phase II Trial Progress with Over…

"Long COVID is a global health crisis, negatively impacting over 100 million people worldwide, significantly reducing their quality of life and imposing substantial economic and social burdens. It puts immense pressure on our health systems and strains economic resources," states Oliver von Stein, CEO of Berlin Cures. "If we don't act now, we face spiraling healthcare costs, lost productivity, and widening social gaps. Our united front of clinical centers across Europe marks a…
PR Newswire
04/03/2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab…

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ®sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024ZUG, Switzerland, March 4, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis...
Nasdaq GlobeNewswire
04/03/2024

Phagenesis, a medical device company specializing in the treatment of swallowing…

With the recent approval of Phagenyx® by the FDA in the United States, the investment is primarily intended to support commercialization in the United States and deepen penetration in Europe. It will also support clinical trials, regulatory activities, as well as research and development of pipeline products. With the recent approval of Phagenyx® by the FDA inthe United States, the investment is primarily intended to support commercialization inthe United Statesand deepen penetration inEurope...
PR Newswire
04/03/2024

Global Feminine Hygiene Products Market Share, Trends, Growth, Opportunity…

Feminine hygiene products are personal care products used for women during menstrual discharge, flow, and alternative sex organ practices. Feminine hygiene products play a vital role in maintaining women's reproductive well-being and promoting safe intimate hygiene practices in the prevention of any form of infection. Usually, these products are made of polymeric fiber, pulp, and fluffy wood, among others. They are particularly concerned with menstruation, vaginal cleanliness, contraception, and…
PR Newswire
04/03/2024

Orion Corporation: Managers' transactions – Niclas Lindstedt

ORION CORPORATIONMANAGERS' TRANSACTIONS4 MARCH 2024 at 13.00 EET Orion Corporation: Managers' transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
04/03/2024

Orion Corporation: Managers' transactions – Jari Karlson

ORION CORPORATIONMANAGERS' TRANSACTIONS4 MARCH 2024 at 13.00 EET Orion Corporation: Managers' transactions – Jari Karlson Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
04/03/2024
Altri  Comunicati